[1] Tenesa A, Dunlop M G. New insights into the aetiology of colorectal cancer from genome-wide association studies[J]. Nat Rev Genet, 2009, 10(6): 353-358. [2] Kellermayer R. Epigenetics and the developmental origins of inflammatory bowel diseases[J]. Can J Gastroenterol, 2012, 26(12): 909-915. [3] Zhu S Y, Bing Y T, Wang X B, et al. CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice[J]. Plos One, 2014, 9(6): e100167. [4] Zeissig S, Kaser A, Dougan S K, et al. Role of NKT cells in the digestive system. III. Role of NKT cells in intestinal immunity[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 293(6): G1101-G1105. [5] Choi C H R, Bakir I A, Hart A L, et al. Clonal evolution of colorectal cancer in IBD[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4): 218-229. [6] Farraye F A, Odze R D, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease[J]. Gastroenterology, 2010, 138(2): 738-745. [7] Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies[J]. J Crohns Colitis, 2015, 9(11): 945-965. [8] Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-based Consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders[J]. J Crohns Colitis, 2017,11(6):649-670. [9] Rubin D T, Ananthakrishnan A N, Siegel C A, et al. ACG Clinical Guideline: ulcerative colitis in adults[J]. Am J Gastroenterol,2019,114(3):384-413. [10] Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer[J]. Cancer Microenviron,2011, 4(2): 141-154. [11] Murray P J, Wynn T A. Protective and pathogenic functions of macrophage subsets[J]. Nat Rev Immunol, 2011, 11(11): 723-737. [12] Popivanova B K, Kitamura K, Wu Y, et al. Blocking TNF-α in mice reduces colorectal carcinogenesis associated with chronic colitis[J]. J Clin Invest, 2008, 118(2): 560-570. [13] Matsumoto S, Hara T, Mitsuyama K, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model[J]. J Immunol, 2010, 184(3): 1543-1551. [14] Sun M, He C, Cong Y, et al. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota[J]. Mucosal Immunol,2015,8(5):969-978. [15] Uzzan M, Colombel J F, Cerutti A, et al. B Cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases[J]. Dig Dis Sci,2016,61(12):3407-3424. [16] Kanga K J W, Mendonca P, Soliman K F A, et al. Effect of diallyl trisulfide on TNF-α-induced CCL2/MCP-1 release in genetically different triple-negative breast cancer cells[J]. Anticancer Res,2021,41(12):5919-5933. [17] McClellan J L, Davis J M, Steiner J L, et al. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1[J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(10): G1087-G1095. [18] Popivanova B K, Kostadinova F I, Furuichi K, et al. Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice[J]. Cancer Res, 2009, 69(19): 7884-7892. [19] Yoon S, Kang B W, Park S Y, et al. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer[J]. J Cancer Res Clin Oncol, 2016, 142(8): 1775-1780. |